ALK: Five-year GRAZAX® Asthma Prevention (GAP) Trial Reveals Benefits of Early Treatment Intervention in Children
Hørsholm, Denmark (ots/PRNewswire) - - The disease modifying property of GRAZAX® (SQ® grass SLIT-tablet) resulted in long-term effect on allergic rhinoconjunctivitis (ARC) and prevented asthma symptoms, even two years after end of treatment in children with grass pollen ARC and no existing signs or symptoms of ...